Hong I. Wan, Ph.D.

President, Chief Executive Officer and Co-founder

Hong I. Wan, Ph.D. is president, chief executive officer and director of Tallac Therapeutics. She co-founded Tallac with Drs. Corey Goodman, Jaume Pons and Curt Bradshaw in 2018. Dr. Wan is a life science leader with over 20 years of drug development experience and expertise in multiple therapeutics areas in biotech and pharmaceutical industry. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.